Laurel Duggan, DCNF
The Florida Department of Health issued new guidance Tuesday advising against Department of Health And Human Services (HHS) recommendations for child sex change procedures and gender transitions.
The Florida Department of Health’s guidance recommends that children with gender dysphoria should not undergo medical or social transitions, in stark contrast to recent HHS recommendations endorsing biomedical interventions, including surgeries, for children.
Today, the Florida Department of Health released guidance pushing back on @HHSGov unscientific shift in the treatment of gender dysphoria for children and adolescents.
— Florida Dept. of Health (@HealthyFla) April 20, 2022
“The point is to give doctors the tools to make the best decisions for their patients,” Jeremy Redfern, press secretary for the Florida Department of Health, told the Daily Caller News Foundation. “That’s especially important now that the federal government is pressuring doctors to perform irreversible medical procedures on children despite a lack of evidence for their effectiveness.”
The guidance comes weeks after Biden’s HHS endorsed “gender-affirming care” for youths, including puberty blockers, hormones and surgeries.
Cross sex hormones, puberty blockers, hormone therapy and social gender transitions should not be administered to children to treat gender dysphoria, the Florida guidance stated, noting that 80% of those seeking clinical care for gender dysphoria will lose their desire to identify as the opposite sex.
Instead, young people who experience persistent gender confusion should receive social support from peers and family as well as professional counseling, the guidance advises.
To transgender Americans of all ages, I want you to know that you are so brave. You belong. I have your back. pic.twitter.com/mD4F0m3rU1
— President Biden (@POTUS) March 31, 2022
The guidance also questioned the quality of existing research on transgender treatments for young people.
“Systematic reviews on hormonal treatment for young people show a trend of low-quality evidence, small sample sizes and medium to high risk of bias,” the guidance said.
HHS did not respond to the Daily Caller News Foundation’s request for comment.
For licensing opportunities of our original content, please contact email@example.com.
DONATE TO BIZPAC REVIEW
- Biden: Musk’s foreign ties are ‘worth being looked at’ after ‘joint acquisition’ of Twitter with ‘other countries’ - November 10, 2022
- With Republicans poised to take back the House, a key opportunity to reverse Dems’ insanity emerges - November 9, 2022
- Elon Musk offloads nearly $4 billion in Tesla stock as shares continue to tank - November 9, 2022